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Abstract
Background: UBQLN2 mutations have recently been associated with familial forms of amyotrophic lateral sclerosis
(ALS) and ALS-dementia. UBQLN2 encodes for ubiquilin-2, a member of the ubiquitin-like protein family which
facilitates delivery of ubiquitinated proteins to the proteasome for degradation. To study the potential role of
ubiquilin-2 in ALS, we used recombinant adeno-associated viral (rAAV) vectors to express UBQLN2 and three of the
identified ALS-linked mutants (P497H, P497S, and P506T) in primary neuroglial cultures and in developing neonatal
mouse brains.
Results: In primary cultures rAAV2/8-mediated expression of UBQLN2 mutants resulted in inclusion bodies and
insoluble aggregates. Intracerebroventricular injection of FVB mice at post-natal day 0 with rAAV2/8 expressing
wild type or mutant UBQLN2 resulted in widespread, sustained expression of ubiquilin-2 in brain. In contrast to
wild type, mutant UBQLN2 expression induced significant pathology with large neuronal, cytoplasmic inclusions
and ubiquilin-2-positive aggregates in surrounding neuropil. Ubiquilin-2 inclusions co-localized with ubiquitin,
p62/SQSTM, optineurin, and occasionally TDP-43, but were negative for α-synuclein, neurofilament, tau, and FUS.
Mutant UBLQN2 expression also resulted in Thioflavin-S-positive inclusions/aggregates. Mice expressing mutant
forms of UBQLN2 variably developed a motor phenotype at 3–4 months, including nonspecific clasping and
rotarod deficits.
Conclusions: These findings demonstrate that UBQLN2 mutants (P497H, P497S, and P506T) induce proteinopathy
and cause behavioral deficits, supporting a “toxic” gain-of-function, which may contribute to ALS pathology.
These data establish also that our rAAV model can be used to rapidly assess the pathological consequences of
various UBQLN2 mutations and provides an agile system to further interrogate the molecular mechanisms of
ubiquilins in neurodegeneration.
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Background
Several mutations in the UBQLN2 gene have recently
been identified and associated with X-linked familial ALS
and ALS-dementia [1–3]. UBQLN2 encodes ubiquilin-2, a
member of the ubiquitin-like family of proteins that facili-
tate delivery of polyubiquitinated proteins to the prote-
asome for degradation [1]. In humans there are at least 4
ubiquilins. Each is widely expressed, except for ubiquilin-3
which is testes specific [4]. Ubiquilins are characterized by
an N-terminal ubiquitin-biding domain (UBA), a variable
number of Sti1-like repeats, and a C-terminal ubiquitin-
like domain (UBL) that associates with the proteasome.
Identified ALS-linked mutations (P497S/H, P506TS/T,
and P525S) are primarily located in a C-terminal proline-
rich domain that contains 12 PXX repeats [1]; however, 3
have been identified outside this region [2]. Recently, an-
other mutation was identified within the proline-rich re-
gion in UBQLN2 and linked to familial ALS (c.1490C > T,
p.P497L) [3]. Mutations in ubiquilin-2 have been proposed
to alter proteasome mediated protein clearance, suggest-
ing a loss-of-function and possible cause for abnormal
protein accumulation and deposition [1]. However,
ubiquilins have also been implicated in ER-associated pro-
tein degradation and autophagy [5–7]. Examination of
protein inclusions in pathological tissue from both spor-
adic ALS and ALS-dementia demonstrate the presence of
ubiquilin-2 in inclusions and co-localization with other
proteins such as ubiquitin and p62/SQSTM1, further sug-
gesting a role for ubiquilin-2 in proteinopathy and in ALS
pathology [1, 8, 9]. Few studies to date, however, have ex-
amined the role of ubiquilin-2 and consequence of identi-
fied mutations—so far limited to P497H mutant—on the
development of ALS pathology [10, 11].
To determine the pathological consequences of
UBQLN2 mutants, we developed rAAV 2/8 vectors to
compare the effects of overexpression of wild type (WT)
and three of the recently identified ALS-mutant ubiquilins
in primary neuroglial cultures and in the developing
mouse brain. In mice we utilized “somatic brain transgen-
esis” (SBT) to rapidly introduce and express UBQLN2mu-
tants in throughout the brain. Although having more
limited and variable expression compared to traditional
transgenic models, SBT still allows for rapid, widespread
expression and screening of genes of interest before
expending the time and expense developing traditional
transgenic models [12, 13]. Our findings demonstrate that
overexpression of pathological forms of mutant ubiquilin-
2 compared to WT all develop widespread inclusion path-
ology, including amyloid-like aggregates, that persists over
6 months and which is associated with mild, early motor
deficits. These studies provide further insight into the
in vivo effects of expression of ALS-linked mutant forms
of ubiquilin-2 in mice. Furthermore, our SBT mouse
models demonstrate a powerful and complementary
approach to traditional transgenics that will allow further
dissection of pathological mechanisms of ubiquilin-2 mu-
tants and their role in development of ALS and ALS-
dementia.
Results
To study the effects of recently described ALS-linked
UBQLN2 mutants on pathology we cloned wild-type
(WT) and three mutant forms of ubiquilin-2 (P497S,
P497H and P506T) into rAAV vectors for expression in
developing mouse brain. Viral expression was first tested
in primary neuroglial cultures before moving to mice.
Viral expression of ubiquilin-2 mutants in mixed neuroglia
cultures results in large punctate intracellular
accumulations
Recombinant AAV2/8 expressing ubiquilin-2 WT or
ALS-linked mutants (P497S, P497H and P506T) was
used to transduce primary neuroglial cultures at DIV +
6. Four days post-transduction cells were analyzed by
immunofluorescence and biochemistry. Neurons were
identified by MAP2 and astrocytes by GFAP co-
immunostaining. Ubiquilin-2 expression was primarily
observed in neurons in E16 cultures, but also seen in
some astrocytes. In cells expressing ubiquilin-2 WT or
pathologic mutants, there was low level of diffuse
ubiquilin-2 immunoreactivity throughout the neuronal
perikarya. Most notably, large accumulations of
ubiquilin-2 were seen in both the neuronal cytoplasm
and processes. Intracellular ubiquilin-2-postive accumu-
lations, although present in cultures transduced with
AAV-UBQLN2(WT), were larger and more prevalent in
cultures transduced with mutant UBQLN2 (Fig. 1a).
Also, neurons transduced with either P497S, P497H or
P506T mutant ubiquilin-2 displayed frequent ubiquilin-
2-postive punctate accumulations in neuronal processes
with a “bead on a string”-like appearance, suggesting an
altered subcellular distribution. These puncta were more
apparent in cultures transduced with the P497H and
P506T UBQLN2 mutants and associated with apparent
dystrophic changes in neurites. Some ubiquilin-2-postive
accumulations were located outside neurons and coloca-
lized with the astrocytic marker GFAP, but not the
microglial marker Iba-1 (Fig. 1b). Preliminary screen to
identify subcellular localization of intracellular ubiquilin-
2 accumulations revealed no colocalization with early
endosomal markers such as EEA1 or Rab5; late endo-
somes, Rab7; autophagosomes, LC3; or lysosomes,
LAMP1 (data not shown).
To further assess viral expression of WT and mutant
ubiquilin-2 in primary cultures, we performed Western
blots on fractionated cell lysates. Notably, mutant forms
of ubiquilin-2, but not WT, accumulated in the SDS
soluble fraction suggesting that ALS-linked mutant
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ubiquilins form Triton X-100 (TX) insoluble aggregates
(Fig. 1c). As mutations in ubiquilin-2 have been sug-
gested to reduce proteasomal degradation [1], we inves-
tigated the effect of expression of different ALS-linked
mutant ubiquilin-2 on UPS function in HEK293 cells
using the reporter d2EGFP. Twenty-four hours post
transfection cells were treated with cyclohexamide and
then harvested at 3 h intervals and assessed for d2EGFP
levels which were normalized to β-actin. Expression of
both the P497S and P506T mutants significantly re-
duced the rate of d2EGFP proteasomal degradation
relative to WT ubiquilin-2 (Fig. 1d). Interestingly, the
P497H mutant showed no change in d2EGFP degrad-
ation compared to WT in contrast to that previously
reported [1].
SBT expression of ubiquilin-2 mutants results in
widespread inclusion pathology
To investigate the role of UBLQN2 and ALS-liked muta-
tions in pathology, we used somatic brain transgenesis
with rAAV serotype 2/8 to express either EGFP-control,
WT or one of three different mutant forms of ubiquilin-
2 (P497S, P497H, and P506T) in the developing mouse
brain. Non-transgenic FVB mice all received bilateral
i.c.v. injections of virus at P0. Mice injected with
rAAV2/8-UBQLN2 wild type and ALS-linked mutants
all demonstrated widespread neuronal (specific) expres-
sion of ubiquilin-2 in the olfactory bulb, cortex, hippo-
campus, thalamus, striatum, brainstem, and cerebellum
as early as 1 month post-injection, and maintained at



























































Fig. 1 Mutant Ubiquilin-2 overexpression results in punctate intracellular accumulations in primary mixed neuroglia cultures. a. Cells transduced
with AAV-UBQLN2(WT) show ubiquilin-2 immunoreactivity (green) diffusely present in the cytoplasm and cell processes with few small punctate
accumulations. In contrast, UBQLN2 mutants (P497S, P497H, and P506T) result in large intracellular ubiquilin-2 accumulations both in neuronal
soma and processes (red, labelled with MAP2). Ubiquilin-2 accumulations in processes have a “bead on a string”-like appearance particularly for
P497H and P506T mutants. b. Some ubiquilin-2 accumulations (green) are outside of neurons and colocalized with astrocytes in culture, labeled
with GFAP-imunoreactivity (red). c. Western blot of TX-soluble and insoluble fractions show that all UBQLN2 mutants and not WT accumulate in
the TX-insoluble/SDS fraction, suggesting formation insoluble aggregates. d. Graph of d2EGFP signal normalized to actin in HEK293 cells
transfected with WT and mutant ubiquilin-2. Both P497S and P506T mutants show impaired proteasomal degradation of the d2EGFP reporter
compared to the P497H mutant and WT ubiquilin-2. *p < 0.05, **p < 0.01
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the injection such as cortex, hippocampus, thalamus and
striatum, nearly 30–40 % neurons were transduced.
Western blots of whole brain tissue lysates similarly in-
dicated sustained ubiquilin-2 expression through the
6 month time point with levels reaching 10–40 % that of
endogenous mouse ubiquilin-2 (Fig. 3). Transduced
neurons expressing human ubiquilin-2, however, were
easily identified by immunohistochemistry relative to
background endogenous mouse ubiquilin-2, suggesting
several-fold overexpression. Expression of WT ubiquilin-
2 in neurons was diffuse, involving the soma and prox-
imal dendrites, and included few small punctate
cytoplasmic accumulations (see Fig. 4, confocal images).
In contrast, expression of each of the mutant forms of
ubiquilin-2 resulted in large intracellular neuronal
inclusions and extensive neuropil aggregates in the sur-
rounding gray matter, similar to that recently described
by Gorrie et al. in transgenic mice with the P497H
mutant ubiquilin-2 [10]. Whereas WT ubiquilin-2 was
mainly cytoplasmic and diffuse, mutant ubiquilin-2 ex-
pression also appeared to have more prominent nuclear
localization. As early as 1 month dystrophic changes
were also seen in the dendritic arbors of purkinje cells
expressing mutant ubiquilin-2, which appeared to have
reduced branching architecture (Fig. 2). Glial markers
showed only a rare ubiquilin-2-positive astrocyte in
areas of abundant viral expression (Fig. 4). Despite the
presence of abundant large inclusion seen in mice ex-
pressing mutant forms of ubiquilin-2, there was no ap-































UBQLN2 wt P497S P506T P497HEGFP 
Fig. 2 Viral expression of ubiquilin-2 at 6 months. Representative schema of sagittal section shows the overall distribution of AAV-UBQLN2 expression in
mouse brain after ICV injection (SBT model). Photos show ubiquilin-2 immunostaining in representative sections animals injected with AAV expressing
either EGFP control or WT vs P497S, P497H, or P506T mutant ubiquilin-2. WT ubiqulin-2 expression is homogeneous throughout the neuronal perykaria,
including processes. Mutant ubiquilin-2 shows altered subcellular expression, often concentrating in the nucleus, but also resulting cytoplasmic inclusions.
Ubiquilin-2-positive “aggregates” are seen also in adjacent neuropil. Arrows point out alteration in purkinje cell dendritic arbors for mutant vs WT ubiquilin-
2. (Scale same for all photomicrographs, bar = 50 μm)
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mice. Tissues were immunostained for apoptotic cell
markers including caspase-3/7 and tunnel stain, and
both negative (data not shown). Examination of
hematoxylin & eosin stained sections also showed no
evident cell loss or degeneration of brain regions overex-
pressing ubiquilin-2.
Mutant ubiquilin-2 inclusions colocalize with TDP-43 and
are ThioS-positive
As ubiquilin-2 has been found colocalized with other
proteins in ALS inclusions, such as ubiquitin, p62, and
FUS [1, 14], we examined brain tissue from mice for co-
localization of these and several other neuropathological
proteins including pSer129-synuclein, tau, phospho-tau,
and TDP-43, which is found both in frontotemporal de-
mentia (FTLD-U) and ALS brains. Minimal differences
were noted in expression patterns between 1, 3, and
6 month mice. As expected, ubiquilin-2-positive inclu-
sions and aggregates co-stained for ubiquitin, p62, and
optineurin (Fig. 5). However, ubiquilin-2 inclusions did
not colocalize with FUS (except for that within nuclei)
or phosphorylated α-synuclein using the pSer129/81A
antibody, which has recently shown also to bind
phosphorylated neurofilament subunit L, or NFL [15]
(data not shown). Inclusions also did not colocalize
with tau, consistent with published data that indicate
no correlation of ubiquilin-2 with tau pathology [16].
However, in mice expressing the mutant ubuiqilin-
2(P506T) cytoplasmic TDP-43 aggregates, immuno-
stained with antibodies to either phospho-TDP-43
(403–404) or (409–410) epitopes, were associated with
ubiquilin-2-positive inclusions (Fig. 6). These findings
suggest that ubiquilin-2(P506T) may be more prone
than the P497S/H mutants to cause proteinopathy in-
volving TDP-43 pathology that is seen in frontotem-
poral dementia (FTD). Interestingly, expression of
mutant forms and not WT, of ubiquilin-2 also resulted
in inclusions or aggregates that stained positive for
ThioflavinS suggesting induction of amyloid pathology
(Fig. 7) further supporting the notion that ALS-linked
ubiquilin-2 mutants induce proteinopathy via misfold-
ing and aggregation of proteins.
Viral SBT of ALS-linked UBQLN2 mutants results in an
early motor deficits
So far in mice aged to 6 months we have not observed
significant cell loss or neurodegeneration as determined
by tunnel, caspase-3/7 or hematoxylin and eosin stain-
ing. However, at 3–4 months several mice expressing
mutant ubiquilin-2 (P497S: 7 of 9, P497H: 2 of 9, and
P506T: 4 of 9 mice) developed a nonspecific clasping
phenotype (Fig. 8a). On rotarod testing mice expressing
mutant ubiquilin-2 also showed significant impairment
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Fig. 3 Viral expression of human ubiquilin-2 in whole brain lysates. Western blots of brain lysates from 3 and 6 month animals demonstrate sus-
tained expression of WT ubiquilin-2 and mutants. In the Trition-X100 soluble fraction (a) three bands are seen for ubiquilin-2: top is mouse
UBQLN2 whereas middle and lower (truncated?) bands represent human UBQLN2. b) Only mutant forms of human UBQLN2 are seen in the Triton
insoluble fractions. c) Graph of human vs endogenous mouse UBQLN2 expression in whole brain (Triton soluble) lysates. N = 2–3 sample each
with mean ± SD ratio shown
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Despite the appearance of relative stable pathological
features, these findings suggest progression of pathology
and that more prolonged expression of ALS-linked
ubiquilin-2 using our novel rAAV model system may re-
sult in a more disease-relevant motor phenotype.
Discussion
UBQLN2 mutations have recently been added to the list
of potential genes that cause familial ALS and ALS-FTD
[1, 2]. UBQLN2 encodes for ubiquilin-2, a member of
the ubiquitin-like family of proteins that facilitate trans-
port of ubiquitinated proteins to the proteasome for
degradation. Although evidence to date suggests that
ALS-linked ubiquilin-2 mutants have reduced proteaso-
mal function and cause a potential loss-of-function [1],
the role of ubiquilin-2 in ALS pathology remains un-
clear. To determine the functional consequences of
ALS-linked UBQLN2 mutations, we developed rAAV
vectors to express WT and three of the identified
ubiquilin-2 mutants (P497, P497H, and P506T) in pri-
mary neuronal cells and in the developing mouse brain.
In primary cultures we found that viral overexpression
of ubiquilin-2 resulted in large intracellular accumula-
tions that were more prominent and distributed along
neuronal processes for mutant forms than for WT
ubiquilin-2. Fractionated lysates from these cultures
demonstrated also that mutant ubiquilin-2, but not WT,
were present in TX-insoluble (SDS soluble) fractions,
suggesting tendency for mutant forms of ubiquilin-2 to
form insoluble aggregates. To determine whether viral
expression ALS-linked mutant ubiquilin-2 could induce
pathological and behavioral abnormalities in mice, we de-
veloped a model system using somatic brain transgenesis,
or SBT, to widely and rapidly overexpress ubiquilin-2 in
the developing mouse nervous system. We demonstrate
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Fig. 4 AAV expression of UBQLN2 WT and mutants is specific to neurons. Images are merged photos of representative cortical areas from 6 month
mice stained with immunofluorescence for NeuN/GFAP/Iba-1 (red), ubiquilin-2 (green), and DAPI (blue). The top 2 rows show colocalization of
ubiquilin-2 accumulations with NeuN-positive neurons. Row 2 includes high-power confocal images that demonstrate differences in the distribution of
ubiquilin-2-containing inclusions in NeuN labeled neurons; large inclusions are seen for all mutant forms in contrast to WT ubiquilin-2. Glial markers
GFAP (row 3) and Iba-1 (row 4) rarely colocalize with ubiquilin-2. (Scale bar = 50 μm unless otherwise noted)
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mutants and aged up to 6 months develop early, wide-
spread neuronal inclusion pathology, dystrophic neurite
changes, and motor deficits.
To date few studies have examined the in vivo conse-
quences of ALS-linked ubquilin-2 in brain and spinal
cord. Recently, Gorrie et al. [10] published the first find-
ings from transgenic mice that express one of the ALS-
linked mutant ubquilin-2 (P497H) under the direction of
the UBQLN2 promoter. Progressive ubiquilin-2 path-



































Fig. 5 Ubiquilin-2 inclusions colocalize with ubiquitin, p62, and optineurin. Merged immunofluorescent images are from a) cortex and b)
hippocampus from 6 month mice and show staining for ubiquitin/p62/optineurin (red), ubiquilin-2 (green), and DAPI (blue). In contrast to WT,
pathological (mutant) ubiquilin-2 form large intracellular and neuropil inclusions that frequently colocalize (indicated as yellow, representing
overlap red and green signal) with ubiquitin, p62, and optineurin. (bar = 25 μm)
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prominent in the hippocampal gyrus, but also in the
frontal and temporal lobes with increasing age, similar
to that seen in human ALS tissues [1]. Abundant
ubiqulin-2-positve neuropil aggregates in gray matter,
but not in white matter, were noted [10] and similar to
that observed in our mouse brains transduced with
rAAV-UBQLN2 mutants. These findings suggest that
ubiquilin-2 aggregates are localized to dendrites rather
than axons. Indeed, electron microscopy studies indicate
primary somatodendritic aggregates which are promin-
ent in dendritic spines in hippocampal and cortical tis-
sues and which may contribute to altered spine density
and plasticity [10]. The findings from our mouse models
are complimentary and together these models indicate
that expression of ALS-linked ubiquilin-2 mutants cause
progressive ubiquilin-2 pathology involving aggregate
formation and proteinopathy. However, the link between
these findings, neurodegeneration, and development of
ALS remains unclear. In both our mouse SBT model
and the UBQLN2P497H transgenic mice, neuronal loss
and neurodegeneration have not been observed. How-
ever, more recently, Wu et al. in a similar transgenic
model in rats did show neuronal loss proceeded by for-
mation of ubiquilin-2 aggregates and evidence of im-
paired autophagy and endosomal function [11]. Lack of
evidence for neurodegeneration in our model may pos-
sibly be explained by relative low viral transduction of
neurons (estimated at 30–40 %, greatest in regions near
the ventricles); however, detailed analyses with both tun-













Fig. 6 TDP43 colocalizes with ubiquilin-2 in mice expressing mutant UBQLN2 (P506T). a) Low power merged immunofluorescent images of CA3
hippocampus from mice injected with rAAV expressing WT or P506T mutant ubiquilin-2 and aged 6 months. TDP43 (red) colocalizes (arrowheads)
with several ubiquilin-2-positive (green) inclusions in mutant P506T expressing mice. (bar = 25 μm) b) Higher power photomicrographs show
cytoplasmic TDP43 puncta stained with the phospho-TDP43 antibody (403–404) within a large cytoplasmic ubiquilin-2-positive inclusion.
(bar = 25 μm) c) Confocal Z-slice section analysis of ubiquilin-2 inclusions (green) similarly demonstrates colocalization of phosphorylated TDP43
(red) in brain tissue from mice expressing mutant UBQLN2 (P506T)
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our study SBT mice expressing mutant UBQLN2 vari-
ably developed clasping and rotarod deficits as early as
3–4 months, which although nonspecific may indicate
progressive pathology and possible later development of
a more disease-relevant motor phenotype. This finding
is in contrast to recent transgenic P497H models that re-
port evidence for cognitive rather than motor deficits
[10, 11], which may have relevance to ALS-FTD and
other neurodegenerative dementias. To fully determine
the utility of our novel rAAV model system, we will need
to further establish the effects of mutant ubiquilin-2 ex-
pression in mouse brain and spinal cord beyond
6 months to determine whether we can induce patho-
logical and phenotypic changes, such as paresis, ex-
pected for ALS/ALS-FTD.
Evidence to date indicates that ubiquilins play import-
ant roles in multiple protein recycling and degradation
pathways, including the UPS, ERAD, and autophagy
[17]. Although the function of ubiquilin-2 remains
unclear, its homology to ubiquilin-1 suggests a similar
Ubiquilin2 | ThioS| DAPI















Fig. 7 Mutant ubiquilin-2 expression induces ThioS-positive inclusions. Photos show Thioflavin-S staining that colocalizes (arrows; yellow in
merged images) with intracellular ubiquilin-2-positive inclusions seen in mice injected with rAAV expressing mutant but not WT ubiquilin-2.






















Fig. 8 Behavioral deficits in mice. a) Mice expressing ALS-mutant ubiquilin-2 develop a clasping phenotype at 3–4 months. b) Rotarod performance
for mice at 3 months expressing mutant ubiquilin-2 P497S (p < 0.0001) and P506T (p < 0.01) was significantly impaired compared to those expressing
WT ubiquilin-2. Data shown as mean ± SEM; N = 9 for each group
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function and role in the UPS and degradation of pro-
teins. Identified ALS-linked mutations in ubiquilin-2 all
localize to a proline-rich (PXX repeat) region that is dis-
tinct from either the N-terminal UBL (ubiquitin-like)
domain that interacts with the proteasome or the C-
terminal UBA (ubiquitin-associated) domain that associ-
ates with ubiquitinated proteins, suggesting that ALS
mutants may leave these functional domains intact.
ALS-linked mutations in ubiquilin-2 have been shown in
vitro to impair proteasomal degradation and these find-
ings appear consistent with its primary function in the
UPS [1]. Recently in vivo data from bigenic mice
expressing both UBQLN2P497H and the ubiquitinated
protein substrate, UbG67V-GFP, appears to support these
findings. UbG67V-GFP accumulated in the brain of
bigenic mice expressing UBQLN2P497H suggesting im-
paired UPS function [10]. Furthermore, ubiquilin-2 de-
posits in brain sections from these mice colocalized with
antibodies to proteasome subunits. These findings ap-
pear to indicate that mutant ubiquilin-2(P497H) may
still function to bring ubiquitinated proteins to the pro-
teasome, but somehow interferes with proteasomal
degradation, leading to accumulation and abnormal de-
position proteins. Our data indicate that ALS-linked
ubiquilin-2 variants may have differential effects on UPS
function. Indeed the P497H mutant had little effect on
d2EGFP levels and was similar to WT, whereas expres-
sion of both the P497S and P506T mutants impaired
d2EGFP metabolism (Fig. 7). These data suggest that al-
ternative protein degradation mechanisms may be in-
volved such as the autophagy-lysosomal system to
explain the effects of these ubiquilin-2 mutants on pro-
teinopathy seen in our models.
Recent studies also implicate ubiquilin-2 in macroau-
tophagy. Early studies demonstrated that ubiquilin-1
binds the target of rapamycin (mTOR) kinase in mam-
malian cells, a critical regulator of macroautophagy [18].
Both ubiquilin-1 and 2 have also been shown to colocal-
ize with the microtubule-associated protein 1 light chain
3 (LC3), a membrane component of autophagosomes,
and have been implicated in the maturation of autopha-
gic vesicles [5]. Notably, knockdown of ubiquilin-2
(and 1) rendered cells expressing either a Alzheimer’s-
related presenilin mutant or a huntingtin polyglutamine
expansion more susceptible to starvation-induced death,
whereas overexpression is protective, further supporting
a role in autophagy and neurodegenerative disease [5].
The effects of ALS-linked mutations on ubiquilin-2
function in macroautophagy have not been explored and
remain unclear. We hypothesize that expression of
ubiquilin-2 mutants may impair macroautophagy, as well
as UPS function, disrupting proteostasis and contribut-
ing to protein accumulation, aggregate formation, cell
stress and cytotoxicity.
To date, few studies have identified protein interactors
with ubiquilin-2 or ALS-linked mutants. UBA and UBL
domains in ubiquilins are known to interact with polyu-
biquitinated proteins and the proteasome, respectively,
consistent with their function in the UPS [4]. In
addition, ubiquilins have been shown to interact with
components of the ERAD including Erasin and p97/
VCP (valosin-containing protein) that form a complex at
the ER membrane to direct degradation of misfolded
protein as part of the unfolded protein response [6].
More recently, ubiquilin-2 was shown to interact with
the ubiquitin regulatory X domain-containing protein 8
(UBXD8), which mediates translocation of ERAD sub-
strates such as p97/VCP, and this interaction was im-
paired by the ubiquilin-2 mutant (P497) [19]. Although
ubiquilin-2 has been colocalized with several other pro-
teins in vitro and in vivo including LC3 [5], p62/
SQSTM1, ubiquitin [1], and optineurin [10], direct inter-
actions have not been demonstrated. Our data indicate
colocalization of ubiquilin-2 inclusions with cytoplasmic,
phospho-TDP-43 in mice expressing the P506T mutant
ubiquilin-2. Recent evidence suggests that ubiquilin-2
binds to C-terminal fragments of TDP-43 [1, 20]. TDP-
43 and in particular mislocalization and aggregation of
C-terminal fragments of TDP-43 have been implicated
in both ALS and FTD pathology. Together, these data
provide an incomplete picture of proteins that may
interact with ubiquilin-2 or ALS-linked mutants that
may be critical to understanding both the normal func-
tion of ubiquilin-2 as well as how identified mutations
alter its function and may influence development of
ALS/ALS-FTD pathology.
Conclusions
We demonstrate using rAAV techniques that overex-
pression of ALS-linked mutant UBQLN2 induce patho-
logical accumulations of ubiquilin-2 in neurons,
insoluble aggregates, and early behavioral deficits in our
SBT mouse model. Our findings lend support to the no-
tion that mutant ubiquilin-2 expression result in a
(toxic) gain of function, disrupting proteostasis.
Although traditional transgenic approaches are being
used to investigate the pathological consequences of
ubiquilin-2 mutant expression in mice [21], we report
here the first use of a novel somatic brain transgenic ap-
proach using rAAV serotype 8 that shows a similar pat-
tern of widespread neuronal inclusion pathology in
brain. This approach has several advantages in that we
are able to relatively rapidly test several of the recently
reported ubiquilin-2 variants and highlight potential dif-
ferences in their pathological effects, as well as noted a
potential relevant motor phenotype not previously re-
ported. Clearly there are several limitations to SBT in-
cluding variability among injections and limited viral
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expression. However, the use of rAAV provides agility to
easily modify future constructs to test specific portions
of the ubiquilin-2 that may differentially affect aggrega-
tion and pathology or to express in select cell types to
address possible non-cell autonomous effects suggested
in ALS [22].
Methods
Cloning and rAAV preparation
Both WT and mutant UBQLN2 (P497S, P497H and
P50T) constructs were generated using PCR and were
subcloned into recombinant adeno-associated viral
(rAAV) vectors, serotype 2, with expression cassette
containing a cytomegalovirus enhancer/chicken beta
actin (CBA) promoter, bovine growth hormone polyA,
and woodchuck hepatitis virus post-transcriptional regu-
latory element (WPRE). AAV control vector expressing
EGFP was prepared as previously described by
Chakrabarty et al. [13]. Recombinant AAV constructs
were packaged into AAV with serotype 2/8 capsid using
methods derived from Zolotukhin et al. [23]. Briefly, we
co-transfected rAAV into HEK293T cells with linear
polyethylenimines (PEI, Polysciences) along with AAV
helper plasmid 8 (Plasmid Factory, Germany). Cells were
harvested, lysed, and virus isolated with an iodixanol
gradient, and then buffer exchanged to sterile PBS,
pH 7.2. Viral titers (genome copies per mL) were deter-
mined by quantitative PCR (Bio-Rad, CFX384) as previ-
ously described and [13]. AAV titers were as follows:
UBQLN2 WT 2.30×1013 gc/mL, P497S 1.38x1013 gc/mL,
P497H 1.30×1013 gc/mL, P506T 1.26×1013 gc/mL, and
EGFP 2×1013 gc/mL. All freshly prepared AAVs were ali-
quoted and stored at −80 °C until use. Neuroglial cul-
tures. Primary mixed neuronal-glial cultures were
prepared as previously described by Sacino et al. [24].
Briefly, mouse cortices from B6C3HF1 mice were iso-
lated at E16. The tissue was dissociated by digestion with
papain solution (Worthington Biochemical Corp, NJ)
and 50ug/ml DNase I (Sigma, MO) at 37 for 20 min.
After digestion cortices were washed three times with
Hank’s Balanced Salt Solution (HBSS, Life Technologies)
to remove the papain and place in media consisting of
Neurobasal (Life Technologies) supplemented with
0.02 % NeuroCult™ SM1 (STEMCELL Technologies Inc.,
Vancouver), 0.5 mM GlutaMax (GIBCO, Life Technolo-
gies), 5 % Fetal Bovine Serum (Hyclone, GE Life
Sciences) and 0.01 % Pen-strep (GIBCO, Life Technolo-
gies). The tissue was triturated in the same media and
dissociated cells were plated in CC2-coated cell Lab-Tek
II 8-chamber slides (Fisher Scientific) at a density of
20,000 cells per well for imaging and in poly-D-lysine
(Sigma, MO) coated 6-well plates for biochemical
analysis. Cells were maintained at 37 °C in a humidified
incubator with 5 % CO2.
Double Immunofluorescence analysis of mixed neuroglia
cultures
Cells were transduced at DIV-6 (days in vitro) with
rAAV2/8 UBQLN2 WT and mutants to a final concentra-
tion of 1011 gc/ml. At DIV-10 cells were fixed with 4 %
paraformaldehyde in PBS (0.01 M phosphate buffered sa-
line, pH 7.4), then washed with PBS and blocked in 5 %
goat serum with 0.1 % triton X-100 in PBS for 1 h, and
then incubated overnight in primary antibodies: UBQLN2
(1:500; Abcam) and MAP2 (1: 1000; Abcam). Cells were
washed in PBS and then incubated in secondary antibody
goat-anti mouse conjugated to Alexa-488 and goat anti-
rabbit conjugated to Alexa-594 (1:1000; Life technologies).
Nuclei were counterstained with mounting media con-
taining 4′,6-diamidino-2-phenylindole (DAPI). Images
were captured using Olympus BX-60 epi-fluorescence
microscope with DP71 digital camera.
Biochemical fractionation followed by western blot analysis
Cells for Western blot were extracted using TBS (tris-
buffered saline) and 1 % triton X-100 supplemented with
proteinase and phosphate inhibitors (TBS-T buffer),
vortexed, and incubated on ice for 5 min. Tissue samples
from adult mouse brain were weighed (wet weight), then
digested mechanically in 4× volume of same lysis buffer
(ice-cool), and similarly incubated on ice for 5 min. Ly-
sates were centrifuge at 100,000 g for 20 min at 4 °C,
the supernatant saved (soluble fraction), and the pellets
re-washed with TBS-T buffer and re-centrifuged with
the same buffers to remove any trace of the soluble frac-
tion. The insoluble fractions were the extracted from the
remaining pellets using 2 % SDS (sodium dodecyl sulfate)
and sonication. Equal amounts of Soluble and Insoluble
fractions were visualized by SDS protein electrophoresis
and detected by mouse monoclonal UBQLN2 antibody
(1:1000; Abcam). Ubiquilin-2 was normalized to actin
(AC15, Sigma) in blots.
Proteasomal assay
HEK293 cells were transfected with a UPS reporter vec-
tor encoding d2EGFP. 24 h post transfection, cells were
re-plated into 12-well plates and transfected with either
wild type or mutant ubiquilin-2. 24 h after second trans-
fection, cells were treated with 30 μg/ml of cyclohexa-
mide (Sigma) for 0, 3, 6, 9, or 12 h. At each time point,
cells were harvested, washed in ice-cold PBS and lysed
in RIPA buffer including protease inhibitors. Equal
amounts of protein were loaded for Odyssey blotting,
and the d2EGFP levels were normalized to β-actin. Data
were collected from three independent experiments.
Mice, neonatal injections, and behavioral assessment
All animal husbandry and procedures were approved by
the University of Florida Institutional Animal Care and
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Use Committee and conformed to the NIH guidelines
for animal research. B5C3HF1 and FVB mice were ob-
tained from Harlan labs (Tampa, FL) for use in these
studies. Neonatal mice were kept with parent mother
until weaned. Mice were otherwise housed three to five
per cage, given food and water ad libitum, and kept on a
12 h light/dark cycle.
AAV were injected in newborn mice P0 (0–24 h old)
as described in Chakrabarty et al. [13]. Briefly, rAAV-
UBQLN2 were delivered to non-transgenic FVB mice
via bilateral intracerebroventricular (i.c.v.) injections.
Each injection included 2 μL rAAV (1–3x1013 gc/mL)
expressing UBQLN2 WT or P497S, P497H, P506T mu-
tant or EFGP (control) into both cerebral ventricles. For
each virus, approximately 12–18 mice were injected
(2–3 litters). Mice were observed and underwent peri-
odic SHIRPA primary screen testing [25]. At 3 months a
subset of mice (n = 9 per group) performed rotarod
testing. Mice were sacrificed at set timepoints: 1 month
(n = 2–3 per group), 3 months (n = 6–8) and 6 months
(n = 6–8) post-injection. Animals were euthanized by
CO2 inhalation, briefly perfused transcardially with PBS,
and brains harvested immediately. Half of the brain was
fixed in 10 % formalin, washed and embedded in paraffin
for sections; the other half was flash-frozen for later
biochemical analysis.
Rotarod testing
Mice were trained in groups of 3–5 on a Rotamex-5 ap-
paratus (Columbus Inst., OH). Mice were given a series
of pre-training trials the day before testing, including 3,
5 min runs on the rotarod at constant speed (5 rpm).
During the following 4 consecutive days, mice were
tested with 4, 5 min trials (40–60 min inter-trial inter-
val) with gradual acceleration of the rod from 4 to
40 rpm. The speed and latency to fall were recorded for
each trial. Best performances from each of the 4 test tri-
als on each consecutive day were analyzed and groups
compared using repeated measures ANOVA.
Immunohistochemistry and immunofluorescence analysis of
brain sections
Paraffin embedded brains were cut into 8 μm sagittal
sections. Sections were deparaffinized and dehydrated in
xylenes and serial alcohol concentrations (70–100 %)
followed by water antigen retrieval, steam, or retrieval
solution (Dako) for 30 min followed by hydrogen-
peroxide incubation. Sections were immunostained with
primary antibody to UBQLN2 (Sigma; 1:500) and other
specific antibodies (as listed below) overnight, and then
developed using Immpress polymer detection reagents
(Vector Labs). Sections were counterstained using
hematoxylin solution. Separate sections also underwent
hematoxylin and eosin staining. Brain images were
scanned using ScanscopeXT image scanner (Aperio/
Leica USA). For double immunofluorescence sections
were immunostained with primary antibody to UBQLN2
(5 F5, Novus Biologicals; or HPA006431, Sigma-Aldrich)
in combination with other antibodies including: ubiqui-
tin (Ab7780, Abcam, Cambridge, MA), p62 (SQSTM1,
Proteintech, Chicago, IL), GFAP (Dako, Carpinteria,
CA), Iba-1 (Abcam), MAP2 (Abcam), caspase 3, α-
synuclein (Syn1, BD Biosciences, San Jose, CA),
pSer129-synclein [26], NFL (neurofilament, C28E10, Cell
Signaling Technologies; or monoclonal NR4, Sigma-
Aldrich), PHF1 (provided by Dr. Peter Davis), TDP-43
(Cosmo Bio, Carlsbad, CA), phospho-TDP43 (403/404
and 409/410 antibodies, Cosmo Bio), FUS (Bethyl,
Montgomery, TX), Matrin-3 (2539C3a, Abcam),
Optineurin (Abcam), and VCP/p97 (Abcam). For
visualization fluorescent conjugated antibodies, Alexa
594-goat anti-mouse or anti-rabbit and Alexa 488-goat
anti mouse at 1:500, were used. Fluorescent images were
captured using either Olympus BX60 microscope with epi-
fluorescence, confocal spinning disc (Olympus DSU-IX81)
or laser confocal microscope (Leica TCS SP2 AOBS
spectral) for analysis.
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